Literature DB >> 2939406

[Incidence of polyneuropathies in chronic obstructive bronchopneumopathies].

B Paramelle, A Vila, P Pollak, P Muller, D Gavelle, F Reymond, C Brambilla, P Stoebner.   

Abstract

In a prospective study 43 patients with chronic obstructive lung disease and severe respiratory insufficiency were systematically investigated for polyneuropathy, although they had no risk factor of that disease. Electrophysiological recordings showed slight or significant signs of polyneuropathy in 17 and 15 patients respectively, thus indicating that the condition is frequent. Clinically, it was often silent or manifested only by sensory disorders predominant in the lower limbs. Electrophysiology suggested axonal degeneration associated with some degree of demyelinization, and these lesions were found at histology to be present in sensory nerves. Histological examination of the muscles showed peripheral mixed neurogenic atrophy probably due to hypoxia. Major thickening of basal material was observed in capillaries of the endomysium and endoneurium. Statistical analysis of clinical parameters and respiratory function values in relation to the presence and importance of polyneuropathy showed that the only significant difference was the longer duration of hypoxia in patients with nerve involvement. Age, alcoholism and the other respiratory function values did not seem to be correlated with lesions of the peripheral nervous system.

Entities:  

Mesh:

Year:  1986        PMID: 2939406

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  11 in total

1.  Endoneurial capillary abnormalities in mild human diabetic neuropathy.

Authors:  R A Malik; A Veves; E A Masson; A K Sharma; A K Ah-See; W Schady; R H Lye; A J Boulton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

Review 2.  Hypoxia, almitrine, and peripheral neuropathy.

Authors:  P Howard
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

3.  Almitrine neuropathy. A nerve biopsy study of 8 cases.

Authors:  R Gherardi; M Baudrimont; F Gray; F Louarn
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

4.  Peripheral neuropathies during treatment with almitrine: report of 46 cases.

Authors:  P Bouche; L Lacomblez; J M Leger; M P Chaunu; H Ratinahirana; P Brunet; J J Hauw; H P Cathala; D Laplane
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

5.  Polyneuropathy associated with chronic hypoxaemia: prevalence in patients with chronic obstructive pulmonary disease.

Authors:  G Pfeiffer; K Kunze; M Brüch; M Kutzner; G Ladurner; J P Malin; W Tackmann
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

6.  Double-blind placebo controlled clinical trial of almitrine bismesylate in patients with chronic respiratory insufficiency.

Authors:  I Bakran; B Vrhovac; B Stangl; D Tabori; A Ivicevic; V Todic; F Kandare
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Microangiopathy of endoneurial vessels in hypoxemic chronic obstructive pulmonary disease (COPD). A quantitative ultrastructural study.

Authors:  P Stoebner; P Mezin; A Vila; R Grosse; N Kopp; B Paramelle
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

8.  Pattern of myelinated fibre loss in the sural nerve in neuropathy related to type 1 (insulin-dependent) diabetes.

Authors:  J G Llewelyn; P K Thomas; S G Gilbey; P J Watkins; J R Muddle
Journal:  Diabetologia       Date:  1988-03       Impact factor: 10.122

9.  Is resistance to ischaemic conduction failure induced by hypoxia?

Authors:  E A Masson; S E Church; A A Woodcock; S P Hanley; A J Boulton
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

10.  Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy.

Authors:  R A Malik; P G Newrick; A K Sharma; A Jennings; A K Ah-See; T M Mayhew; J Jakubowski; A J Boulton; J D Ward
Journal:  Diabetologia       Date:  1989-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.